News & Analysis on Clinical Trial Services & Contract Research And Development
According to a new study, the microscopy sector is set to capitalise on recent technological breakthroughs, with the large-scale digitalisation and advances in image reconstruction and restoration having a positive effect on the market.
US biotechnology company Biogen Idec has said that it plans to sell a California manufacturing plant built to produce its withdrawn multiple sclerosis drug Tysabri (natalizumab) to Genentech, reports Phil Taylor.
Australian drug delivery company Acrux, which specialises in administering medicines through the skin, has reported clinical results of a contraceptive for women in the form of a spray, reports Phil Taylor.
In the US, the National Institutes of Health has awarded $88.9 million in grants to nine institutions over three years to establish a collaborative research network that will use high-tech screening methods to identify small molecules that can be used...
Indian pharmaceutical company Matrix Laboratories is aiming to buy a 22 per cent controlling stake in Belgium's Docpharma in what is the largest overseas acquisition yet in India's drug industry, reports Phil Taylor.
New drug treatments and therapies for the management of bowel cancer is a distinct possibility after researchers made a surprising discovery about the immune system that details how the body expels parasitic worms.
In-PharmaTechnologist provides its periodic round-up of new deals and developments in the pharmaceutical contract manufacturing sector.
A handful of Alzheimer’s drug treatments and lifestyle-based interventions shared the spotlight at the first ever Alzheimer’s Association Prevention conference, in which scientists worldwide took the opportunity to showcase the latest approaches to...